Science Current Events | Science News | Brightsurf.com
 

Vaccine yielded encouraging long-term survival rates in certain patients with NSCLC

April 04, 2012

CHICAGO - Long-term follow-up of a phase II clinical trial showed encouraging survival in some patients with stage 3B/4 non-small cell lung cancer treated with belagenpumatucel-L, a therapeutic vaccine. The findings were presented here at the AACR Annual Meeting 2012, held March 31 - April 4.

"This is a novel immunotherapy that appears to show unusually long survival in some patients," said Lyudmila Bazhenova, M.D., associate clinical professor at the University of California-San Diego Moores Cancer Center in La Jolla, Calif.

These findings represent an updated long-term survival analysis on patients treated with belagenpumatucel-L, a cell-based allogeneic vaccine derived from four lung cancer cell lines. The open-label study included 75 patients with non-small cell lung cancer (NSCLC) - two patients with stage 2 disease, 12 with stage 3A, 15 with stage 3B and 46 with stage 4. The researchers randomly assigned patients to three dose cohorts: 1.25, 2.5 or 5 × 107 cells/injection.

For all patients, median survival was 14.5 months, and the five-year survival rate was 20 percent. The 40 patients with stage 3B/4 cancer enrolled in the second and third dose cohorts had a median survival of 15.9 months and a one-year survival rate of 61 percent, a two-year survival rate of 41 percent and a five-year survival rate of 18 percent.

Patients with stage 3B/4 nonprogressive disease after chemotherapy had a median survival of 44.4 months; five-year survival was 50 percent, which is "unheard of for patients with NSCLC," Bazhenova said.

In contrast, patients who progressed after front-line chemotherapy had a median survival rate of 14.1 months and a 9.1 percent five-year survival rate.

Bazhenova said that although these results are intriguing, they must be confirmed in a phase III clinical trial, which is currently under way in eight countries.

American Association for Cancer Research


Related Non-small Cell Lung Cancer Current Events and Non-small Cell Lung Cancer News Articles


Investigational CDK4/6 inhibitor abemaciclib is active against a range of cancer types
The investigational anticancer therapeutic abemaciclib, which targets CDK4 and CDK6, showed durable clinical activity when given as continuous single-agent therapy to patients with a variety of cancer types, including breast cancer, non-small cell lung cancer (NSCLC), glioblastoma, and melanoma, according to results from a phase I clinical trial.

Preliminary results comparing PD-L1 IHC diagnostic assays in lung cancer released
A pre-competitive consortia of pharmaceutical companies, diagnostic companies, and academic associations, including the International Association for the Study of Lung Cancer (IASLC), announced phase I results of the "BLUEPRINT PD-L1 IHC ASSAY COMPARISON PROJECT" at the Annual Meeting of the American Association for Cancer Research (AACR) on April 19.

Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer (NSCLC) with a type of radiotherapy called stereotactic body radiation therapy (SBRT) is associated with a small but increased risk of death from causes other than cancer.

Plasma genotyping to predict treatment benefit in patients with NSCLC
The benefit of plasma genotyping to predict treatment benefit in patients with non-small-cell lung cancer (NSCLC) is confirmed in three studies presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland.

New tool mines whole-exome sequencing data to match cancer with best drug
A University of Colorado Cancer study published today in the Journal of the American Medical Informatics Association (JAMIA) describes a new tool that interprets the raw data of whole exome tumor sequencing and then matches the cancer's unique genetics to FDA-approved targeted treatments.

Researchers identify potential targeted therapy for lung cancer using fly model
A drug approved by the Food and Drug Administration (FDA) for melanoma in combination with a common cholesterol-lowering drug may show promise in controlling cancer growth in patients with non-small cell lung cancer (NSCLC), according to new research from the Icahn School of Medicine at Mount Sinai.

Improving access to clinical trials when biopsies are required
The requirement for tumor tissue specimens and associated analyses in order to participate in clinical trials appears to be a significant barrier to clinical trial enrollment and may delay treatment.

Three hits to fight lung cancer
Although the most common type of lung cancer - non-small cell lung cancer (NSCLC) - has recently seen major treatment advances in some genetic subtypes, other subtypes continue to evade effective treatment.

Non-small cell lung cancers can be sorted in clusters by endocytic changes
In the Age of Personalized Medicine, we've learned that one size doesn't fit all, least of all in cancer. Cancer is a disease of your cells, and sorting out your cancer from all others is a daunting challenge but one that cancer cell biologists are furiously pursuing.

Researchers identify biomarker of early lung cancer that may increase survival
Researchers in Taiwan have identified a biomarker that detects the most common lung cancer in its earliest stage. The discovery could one day change how long lung cancer patients live.
More Non-small Cell Lung Cancer Current Events and Non-small Cell Lung Cancer News Articles

NCCN Guidelines for Patients®: Lung Cancer (Non-Small Cell), Version 1.2016

NCCN Guidelines for Patients®: Lung Cancer (Non-Small Cell), Version 1.2016
by National Comprehensive Cancer Network® (NCCN®) (Author)


From the medical leaders of 27 of the world’s most renowned cancer centers united under the National Comprehensive Cancer Network® (NCCN®), comes this essential guide to lung cancer (non-small cell lung cancer). Adapted from clinical treatment guidelines used by physicians and oncology professionals around the world, these NCCN Guidelines for Patients® are packed with the latest information, treatment innovations, and resources about the diagnosis and treatment of lung cancer. Each patient-friendly chapter prepares patients and caregivers to talk with their doctors and make treatment decisions. Let this authoritative handbook be your guide! Part 1 – Lung cancer basics – Explains where lung cancer starts and how it spreads. Part 2 – Assessing lung nodules – Discusses care for...

Non-Small Cell Lung Cancer: Across the Continuum of Care

Non-Small Cell Lung Cancer: Across the Continuum of Care
by Asante Communications, LLC


This Clinical Resource Tool is structured around consensus statements developed by the Non-Small Cell Lung Cancer (NSCLC) Working Group, a panel of oncologists with particular expertise in the multidimensional care of patients with advanced lung cancer. Using a modified Delphi process, the NSCLC Working Group has consolidated published evidence and expert clinical experience on critical issues pertaining to the comprehensive assessment of patients with advanced NSCLC, formulation of appropriate treatment regimens, implementation of maintenance therapy, and therapeutic alliances among pathologists, oncologists, and pulmonologists. The consensus statements and accompanying resources are intended as a practical companion to current guidelines, helping clinicians individualize best-practice...

Fast Facts: Non-Small-Cell Lung Cancer: NSCLC

Fast Facts: Non-Small-Cell Lung Cancer: NSCLC
by Benjamin Besse (Author)


Rapid developments in the classification, screening and treatment of non-small-cell lung cancer (NSCLC) are improving outcomes for patients with the disease. This insightful guide is designed to bring you up to speed with recent advances, including: - the latest CT-based screening and interval growth imaging techniques - proposed changes to the TNM classification system - the increasing trend for minimally invasive and lung-sparing surgery - stereotactic radiation for early-stage tumors - new targeted therapies - breakthroughs in personalized medicine. Today's developments will change tomorrow?s standards of care. Fast Facts: Non-Small-Cell Lung Cancer is important reading for all health professionals and medical trainees working in this fast-moving area.

Living With A Diagnosis Of Lung Cancer

Living With A Diagnosis Of Lung Cancer
by Joan Schiller MD (Author)


"Living With a Diagnosis of Lung Cancer” is an easy-to-understand booklet written to help lung cancer patients understand their diagnosis and their options as they face the disease. Lung cancer claims more lives than breast, prostate, and colon cancers combined. In fact, over 288,000 people are diagnosed each year in the U.S. People with lung cancer often are told, "Get your affairs in order." But, there is hope for those diagnosed with lung cancer. Thanks to research advances, there are options available to patients diagnosed regardless of the stage of the disease. Much progress is being made with new treatments being developed and tested each day. This valued resource will help you know what questions to ask of your medical team and can help you understand your treatments...

Personalized Medicine Concept in Non Small Cell Lung Cancer Therapy: The Future is Now

Personalized Medicine Concept in Non Small Cell Lung Cancer Therapy: The Future is Now
by Talath Fatima (Author), Syed Abdul Azeez (Author)


Non Small Cell Lung Cancer (NSCLC) is a heterogeneous, complex and most common cause of cancer-related mortality accounting for about 85-87% of lung cancer cases worldwide .Personalized medicine is a tailored therapy that provides a significant precision and positive result for individual patients. It facilitates the choice of most favorable treatment and diminishes “One size fits all” prescribing. The biomarkers help to gain the efficacy of personalized therapy in alleviating the outcomes of a disease. Molecular Diagnostics is the cornerstone in the development of personalized medicine. It is basically the technique, where molecular biology is applied in medical diagnosis to study the molecular processes inside the body. There has been a remarkable development in the field of...

What You Need to Know About Small Cell Lung Cancer - It's Your Life, Live It! (Volume 1)

What You Need to Know About Small Cell Lung Cancer - It's Your Life, Live It! (Volume 1)
by Michael Braham (Author)


Selecting the right treatment can literally make the difference between life and death. It is important to have the peace-of-mind knowing that you have done everything possible to help fight Small Cell Lung cancer successfully. The Cancer Group Institute's book explains, in plain English, the definition, types, frequency, risk factors, symptoms, historic and latest effective treatment for Small Cell Lung cancer. We describe surgery, radiation, chemotherapy and immune therapies. We tell you everything you must know to help make the right choices today for a Small Cell Lung cancer problem. Some of the Department Heads, Hospitals and Residents using our materials are Mayo Clinic, Harvard University, Columbia, NYU, UCLA, Johns Hopkins, MD Anderson Cancer Center Orlando, Tift Regional...

Lung Cancer Cures:How To Heal LUNG Cancer Natrually: NATRUAL CURES, LUNG CANCER TREATMENT,HEALTH AND FITNESS, NON-SMALL CELL LUNG CANCER, SMALL CELL LUNG CANCER, METASTATIC LUNG CANCER

Lung Cancer Cures:How To Heal LUNG Cancer Natrually: NATRUAL CURES, LUNG CANCER TREATMENT,HEALTH AND FITNESS, NON-SMALL CELL LUNG CANCER, SMALL CELL LUNG CANCER, METASTATIC LUNG CANCER


Find Out How To Cure Cancer Without Chemotherapy And Radiation.
Are You Tired Of Chemotherapy And Radiation?

Have You Ever Wondered How Effective Natural Cancer Treatments Can Be?
Around 20 Years Ago, My Father Was Diagnosed With Breast Cancer. This Was Crazy For My Family At The Time Because My Dad Was A Gym Teacher, Swim Instructor And Was Always Considered To Be “healthy.”

After His Diagnosis, He Took The Advice Of His Oncologists At The Cleveland Clinic And Underwent A Mastectomy Followed By Many Rounds Of Chemotherapy. I Can Still Remember Seeing My Dad’s Hair Fall Out And Thinking He Had Aged 10 Years In The Few Weeks Following Chemo.

Praise Yahawah, After All Of His Treatments, He Was Diagnosed As Being “cancer-free” And Healthy....

Being Mortal: Medicine and What Matters in the End

Being Mortal: Medicine and What Matters in the End
by Atul Gawande (Author)



In Being Mortal, bestselling author Atul Gawande tackles the hardest challenge of his profession: how medicine can not only improve life but also the process of its ending

Medicine has triumphed in modern times, transforming birth, injury, and infectious disease from harrowing to manageable. But in the inevitable condition of aging and death, the goals of medicine seem too frequently to run counter to the interest of the human spirit. Nursing homes, preoccupied with safety, pin patients into railed beds and wheelchairs. Hospitals isolate the dying, checking for vital signs long after the goals of cure have become moot. Doctors, committed to extending life, continue to carry out devastating procedures that in the end extend suffering.Gawande, a practicing surgeon, addresses his...

NCCN Guidelines for Patients®: Non-Small Cell Lung Cancer

NCCN Guidelines for Patients®: Non-Small Cell Lung Cancer
by National Comprehensive Cancer Network® (NCCN®) (Author)


[ THIS BOOK IS OUT OF DATE ] For the latest edition see NCCN Guidelines for Patients: Lung Cancer, Version 1.2016

Lung Cancer

Lung Cancer
by Jack A. Roth (Editor), Waun Ki Hong (Editor), Ritsuko U. Komaki (Editor)


The best and most concise single source for state-of-the-art diagnosis and treatment of lung cancer –newly revised, updated, and expanded.

Lung cancer has long been the number-one cause of death from cancer every year and the third most frequently diagnosed after breast and prostate cancers. In 2010, about 15% of all cancer diagnoses and 30% of all cancer deaths were due to lung cancer. Needless to say, there is a great need for more rapid advancements in diagnosis and treatment of this devastating disease. Here is the comprehensively revised, updated, and expanded edition of the well-established, evidence-based reference book that deals with the most recent advances in lung cancer prevention, screening, diagnosis, research, and treatment for the clinician. Edited and...

© 2016 BrightSurf.com